40–60% of all patients with malignant melanoma show an activating mutation of the serine-threonine kinase B-RAF (BRAF) [3, 4], the most common BRAF mutation being the V600E point mutation (T→ A nucleotide change). This evidence concerns the gene BRAF and melanoma.